Twist Bioscience is overbought with RSI at 72 and already 28% above analyst price targets, carrying 31% short interest and burning cash at 14% of revenue, while concentration in synthetic DNA products and a sole-source supplier create compounding risks.
Thesis pillars
- Severe Negative Asymmetry→Stable
- Synthetic Dna Supplier Concentration→Stable
- Cash Burn 31 Percent Short→Stable
- +1 more pillar — see the Why tab for full reasoning
Twist Bioscience Corporation (TWST) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $100.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 36%; Elevated put/call ratio: 6.52; Below-average business quality.
Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS tools, and biopharma services to more than 3,800 customers in healthcare, chemicals/materials, academic research, and food/agriculture. The company reported $376.6... Read more
Sell if holding. Engine safety override at $100.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 36%; Elevated put/call ratio: 6.52; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Twist Bioscience Corporation
About Twist Bioscience Corporation
Twist Bioscience generated $376.6 million in revenue in fiscal year 2025, split across healthcare ($215.1 million), chemicals/materials ($93.2 million), academic research ($65.9 million), and food/agriculture ($2.4 million). The company served more than 3,800 customers and employs 412 people in manufacturing and operations and 91 in research and development as of September 30, 2025. Substantially all revenue to date comes from synthetic DNA products.
Twist generates revenue through two primary product lines — synthetic biology tools and NGS tools — plus biopharma services for antibody discovery and optimization. Synthetic biology products include synthetic genes, gene fragments, oligo pools, and IgG proteins; NGS tools include library preparation kits, human exome kits, fixed and custom panels, and Alliance panels. The company sells through a direct salesforce and e-commerce platform, employing 278 people in sales, marketing, and customer support as of September 30, 2025. Biopharma partnerships generate revenue through licensing fees, fee-for-service arrangements, and success-based milestones; as of September 30, 2025, Twist had signed 442 revenue-generating partnerships with clients including Bayer, Boehringer Ingelheim, and Takeda Pharmaceutical, with 82 programs including milestones and/or royalties. In October 2024, Twist agreed with XOMA Royalty to receive $15 million cash in exchange for 50% of future milestone and royalty payments from existing collaborations. In synthetic biology, the company competes with GenScript Biotech Corporation and Integrated DNA Technologies (owned by Danaher Corporation); in NGS tools, with Thermo Fisher Scientific, Illumina, and Roche Holding AG.
Show full overview
The 10-K discloses that Twist depends on one single-source supplier for a critical component of its DNA synthesis process. Although Twist maintains a reserve of supplies and acknowledges that alternative suppliers exist, the loss of this supplier or failure to supply the necessary component on time could cause delays in future capacity and may impact operations — a notable risk given that the gene synthesis business requires manufacturing to run 24 hours a day, seven days a week, 365 days per year with no seasonal slack. The filing does not name the supplier or the specific component.
See also: Healthcare · Diagnostics & Research
From Twist Bioscience Corporation's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-29Recent Developments — Twist Bioscience Corporation
Latest news
- NEWS Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107 — benzinga Jun 29, 2026 positive
- NEWS Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95 — benzinga Jun 24, 2026 positive
- NEWS Twist Bioscience Files Prospectus For Offering Mixed Shelf; Terms Undisclosed — benzinga Jun 18, 2026 neutral
- NEWS TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $89 — benzinga Jun 15, 2026 positive
- NEWS Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90 — benzinga Jun 15, 2026 positive
Generated 2026-06-30T02:23:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsynthetic DNA products10-K Item 1A: 'Substantially all of our revenue generated to date is from our synthetic DNA products'
- HIGHSuppliersingle-source supplier10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 6.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -19.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $100.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 36%; Elevated put/call ratio: 6.52; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $92.85. Score 4.5/10, moderate confidence.
Take-profit target: $102.15 (+2.3% upside). Prior stop was $92.85. Stop-loss: $92.85.
Concentration risk — Product: synthetic DNA products; Concentration risk — Supplier: single-source supplier; Target reached (-35.4% upside).
Twist Bioscience Corporation trades at a P/E of N/A (forward -130.8). TrendMatrix value score: 1.8/10. Verdict: Sell.
15 analysts cover TWST with a consensus score of 4.5/5. Average price target: $74.
What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS...
Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, selling synthetic genes, NGS tools, and biopharma services to more than 3,800 customers in healthcare, chemicals/materials, academic research, and food/agriculture. The company reported $376.6 million in revenue in fiscal year 2025, generating fees through product sales and biopharma partnership milestones.